QQQ   270.32 (-0.79%)
AAPL   110.62 (-1.06%)
MSFT   205.03 (-1.15%)
FB   255.20 (+0.18%)
GOOGL   1,437.84 (-1.51%)
AMZN   3,084.59 (-1.42%)
NVDA   503.49 (-0.40%)
TSLA   397.70 (-6.25%)
BABA   275.87 (+0.21%)
CGC   14.96 (-6.73%)
GE   6.30 (+0.80%)
MU   50.62 (+1.85%)
AMD   76.93 (-0.99%)
T   28.36 (-0.53%)
F   6.76 (-0.29%)
ACB   5.56 (-24.04%)
GILD   63.94 (+0.85%)
NFLX   483.15 (-1.63%)
DIS   125.11 (-1.65%)
BAC   23.93 (-0.04%)
BA   156.31 (-0.31%)
QQQ   270.32 (-0.79%)
AAPL   110.62 (-1.06%)
MSFT   205.03 (-1.15%)
FB   255.20 (+0.18%)
GOOGL   1,437.84 (-1.51%)
AMZN   3,084.59 (-1.42%)
NVDA   503.49 (-0.40%)
TSLA   397.70 (-6.25%)
BABA   275.87 (+0.21%)
CGC   14.96 (-6.73%)
GE   6.30 (+0.80%)
MU   50.62 (+1.85%)
AMD   76.93 (-0.99%)
T   28.36 (-0.53%)
F   6.76 (-0.29%)
ACB   5.56 (-24.04%)
GILD   63.94 (+0.85%)
NFLX   483.15 (-1.63%)
DIS   125.11 (-1.65%)
BAC   23.93 (-0.04%)
BA   156.31 (-0.31%)
QQQ   270.32 (-0.79%)
AAPL   110.62 (-1.06%)
MSFT   205.03 (-1.15%)
FB   255.20 (+0.18%)
GOOGL   1,437.84 (-1.51%)
AMZN   3,084.59 (-1.42%)
NVDA   503.49 (-0.40%)
TSLA   397.70 (-6.25%)
BABA   275.87 (+0.21%)
CGC   14.96 (-6.73%)
GE   6.30 (+0.80%)
MU   50.62 (+1.85%)
AMD   76.93 (-0.99%)
T   28.36 (-0.53%)
F   6.76 (-0.29%)
ACB   5.56 (-24.04%)
GILD   63.94 (+0.85%)
NFLX   483.15 (-1.63%)
DIS   125.11 (-1.65%)
BAC   23.93 (-0.04%)
BA   156.31 (-0.31%)
QQQ   270.32 (-0.79%)
AAPL   110.62 (-1.06%)
MSFT   205.03 (-1.15%)
FB   255.20 (+0.18%)
GOOGL   1,437.84 (-1.51%)
AMZN   3,084.59 (-1.42%)
NVDA   503.49 (-0.40%)
TSLA   397.70 (-6.25%)
BABA   275.87 (+0.21%)
CGC   14.96 (-6.73%)
GE   6.30 (+0.80%)
MU   50.62 (+1.85%)
AMD   76.93 (-0.99%)
T   28.36 (-0.53%)
F   6.76 (-0.29%)
ACB   5.56 (-24.04%)
GILD   63.94 (+0.85%)
NFLX   483.15 (-1.63%)
DIS   125.11 (-1.65%)
BAC   23.93 (-0.04%)
BA   156.31 (-0.31%)
Log in
NASDAQ:PRAH

PRA Health Sciences Price Target, Predictions & Analyst Ratings

$102.09
+2.26 (+2.26 %)
(As of 09/23/2020 11:12 AM ET)
Add
Compare
Today's Range
$98.78
Now: $102.09
$102.20
50-Day Range
$97.84
MA: $103.38
$108.65
52-Week Range
$58.67
Now: $102.09
$113.32
Volume2,557 shs
Average Volume423,067 shs
Market Capitalization$6.53 billion
P/E Ratio31.32
Dividend YieldN/A
Beta1.02

Analyst Ratings

PRA Health Sciences (NASDAQ:PRAH) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for PRA Health Sciences in the last 12 months. Their average twelve-month price target is $105.75, predicting that the stock has a possible upside of 3.59%. The high price target for PRAH is $120.00 and the low price target for PRAH is $89.00. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
PRAH Consensus Rating: HoldHoldHoldBuy
PRAH Consensus Rating Score: 2.232.232.422.56
PRAH Analyst Ratings: 2 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
PRAH Consensus Price Target: $105.75$105.75$101.00$110.38
PRAH Price Target Upside: 3.59% upside0.17% downside14.37% upside39.20% upside

PRA Health Sciences (NASDAQ:PRAH) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

PRA Health Sciences (NASDAQ:PRAH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2020UBS GroupBoost Price TargetNeutral$105.00 ➝ $111.00Medium
8/10/2020BofA SecuritiesDowngradeBuy ➝ Underperform$110.00 ➝ $100.00Low
8/10/2020MizuhoBoost Price TargetNeutral ➝ In-Line$92.00 ➝ $108.00Low
8/10/2020CitigroupBoost Price TargetNeutral$90.00 ➝ $110.00Low
8/10/2020Bank of AmericaDowngradeNeutral ➝ Underperform$100.00Low
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$113.00 ➝ $116.00Medium
5/4/2020SunTrust BanksBoost Price TargetBuy$89.00 ➝ $103.00Low
5/4/2020Robert W. BairdLower Price TargetOutperform$106.00 ➝ $101.00Medium
5/1/2020William BlairDowngradeOutperform ➝ Market PerformHigh
4/13/2020Wolfe ResearchDowngradeOutperform ➝ Market Perform$97.00Medium
3/26/2020BarclaysLower Price TargetOverweight$123.00 ➝ $114.00Medium
3/23/2020Jefferies Financial GroupLower Price TargetBuy$125.00 ➝ $89.00Low
1/10/2020Goldman Sachs GroupDowngradeBuy ➝ Neutral$130.00 ➝ $120.00High
7/2/2019SVB LeerinkReiterated RatingMarket PerformMedium
10/4/2018Evercore ISIInitiated CoverageIn-Line ➝ Inline$120.00High
8/2/2018KeyCorpReiterated RatingBuy$115.00Low
12/15/2017Mitsubishi UFJ Financial GroupInitiated CoverageOverweight$102.00Low
(Data available from 9/23/2018 forward)
This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.